Ion Beam Applications (IBA) has selected the ‘Licensed to Cure for Medical Device’ industry solution experience from Dassault Systèmes.
A leading medical device manufacturer and a pioneer in the use of proton beam therapy for cancer treatment, IBA wanted to transition from a labour-intensive, engineered-to-order approach to a standardised collaborative development approach.
The challenge of accommodating for significant advancements in the field of medical research, as well as meeting the needs of a growing global population, is one all medical device manufacturers are facing.
Developing innovative and safe equipment which complies with stringent national and international regulations is a further challenge. With the ‘Licensed to Cure for Medical Device’ solution, IBA’s global teams can gain centralised access to the most up to date design, regulatory and quality information, thus ensuring regulatory compliance.
Product data is easily accessible with the new solution, simplifying the response process when regulatory body’s request information. IBA has full traceability and is able to tightly secure its intellectual property.
“With ‘Licensed to Cure for Medical Device’ we will have a single unifying development framework in which we can capitalise all our data, processes and methodologies for future reuse, and from there improve the productivity of all downstream processes,” said Thomas Canon, PLM Program manager at IBA.
The industry solution experience is based on Dassault Systèmes’ 3DEXPERIENCE platform, which runs on Microsoft Windows, and the company’s ENOVIA V6 software.
“Medical device manufacturers have a dual responsibility: to patients for innovative therapeutic solutions, and to regulatory bodies that must ensure that their equipment abides by stringent safety and quality protocols,” said Monica Menghini, executive vice president, Corporate Strategy, Industry and Marketing, Dassault Systèmes. “The integrated ‘Licensed to Cure for Medical Device’ industry solution experience gives the Life Science Industry a competitive means to provide a faster reply to operators’ needs and, ultimately, faster accessibility to therapies for the patients.”
Share this story